"The… vaccine has been specially created for the population cohorts with immunodeficiency that represents a big significance for the countries where niduses are met. This vaccine is an analogue of the British one and its main mechanism is the significant activation of cellular immunity more than in 35 times. The vaccine's efficiency exceeds the British analogue," Skvortsova said.
She added that the second vaccine had shown 100 percent results in neutralization of Ebola virus.
An Ebola outbreak began in December 2013, spreading across Western Africa from Guinea to Liberia and Sierra Leone killing over 11,000 people in these three countries.